Bladder Cancer

The FDA has granted accelerated approval to avelumab (Bavencio) for treating locally advanced or metastatic urothelial carcinoma patients whose disease progressed following treatment with platinum-containing chemotherapy.

The FDA has approved durvalumab (Imfinzi) for the treatment of patients with advanced urothelial carcinoma whose disease has progressed after treatment with platinum-containing chemotherapy.

The FDA has expanded its approval of atezolizumab (Tecentriq) for the treatment of advanced bladder cancer to include the initial therapy of patients who are not eligible for cisplatin chemotherapy.

This video examines a study that used liquid biopsies to monitor disease progression in patients with bladder cancer.

The PD-L1 antibody avelumab was well tolerated and had promising antitumor activity in patients with refractory metastatic urothelial carcinoma.

Maintenance vinflunine yielded longer progression-free survival vs best supportive care in advanced urothelial carcinoma patients after disease control with chemotherapy.

Sorafenib, gemcitabine, and cisplatin had promising activity and was well tolerated in patients with muscle-invasive urothelial bladder cancer.

Long-term data from the phase III BC2001 trial confirmed that adding chemotherapy to radiation therapy improves locoregional control and reduces the rate of salvage cystectomy in patients with muscle-invasive bladder cancer.

Dr. Roland Seiler presented an analysis of how different bladder cancer molecular subtypes respond to neoadjuvant chemotherapy at the 2017 ASCO Genitourinary Cancer Symposium.

Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy, according to a retrospective, non-randomized study.

Intravesical rAd-IFNα/Syn3 showed promising response rates, a tolerable treatment schedule, and acceptable toxicity among patients with high-grade, nonmuscle-invasive bladder cancer, refractory or relapsed after bacillus Calmette-Guérin therapy.

In this interview we discuss the latest clinical news in urothelial carcinoma, what we’ve learned about the biology of these tumors, and how treatment of this disease has evolved.

Though it is used infrequently, lymph node dissection with higher yield of lymph nodes is associated with lower all-cause mortality among patients with urothelial carcinoma of the upper urinary tract who undergo nephroureterectomy.

The PD-1 inhibitor pembrolizumab yielded significantly improved overall survival vs chemotherapy as second-line treatment in advanced urothelial cancer.

We spoke with Dr. Monika Joshi on the use of radiation therapy and durvalumab in patients with locally advanced bladder cancer.

The PD-1 inhibitor pembrolizumab showed promising antitumor activity and acceptable safety in patients with advanced urothelial cancer, in a phase I trial.

In patients with upper tract urothelial carcinoma, adjuvant chemotherapy following radical nephroureterectomy confers a survival advantage compared with observation following radical nephroureterectomy.

The FDA has concluded that pioglitazone, used to treat type 2 diabetes, may be linked to an increased risk of bladder cancer.

The US Food and Drug Administration has accepted the first Biologics License Application for durvalumab (MEDI4736) to treat patients with urothelial cancer (UC) for whom cisplatin failed to stop disease progression.

The immune checkpoint antibody pembrolizumab (Keytruda, Merck) improved survival in previously treated advanced urothelial cancer compared to chemotherapy, according to the manufacturer of the immunotherapy.

New immunotherapies that target PD-1 are now showing promise for first-line and second-line treatment of metastatic bladder cancer.

The gene known as β-Klotho (KLβ) appears to play an important role in tumor invasion and progression in patients with bladder cancer, and urine KLβ levels may act as a useful biomarker, according to a new study.

Investigators at the University of Colorado Cancer Center and Yale University are now reporting in the journal Cancer Cell on a new understanding of the cancer suppressing gene RhoDGI2 and how it may be involved in metastatic bladder cancer.

Patients with non-urothelial bladder cancer are more commonly upstaged during surgery compared with urothelial cancers.

A small genomic study of patients with chemoradiation-treated urothelial carcinoma of the bladder found similar mutation patterns between primary and recurrent tumors.